ClinConnect ClinConnect Logo
Search / Trial NCT03160131

Rehabilitation of Visual Function After Brain Injury

Launched by UNIVERSITY HOSPITAL, GENTOFTE, COPENHAGEN · May 17, 2017

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Stroke Visual Impairment Hemianopia Neuro Vision Technology Rehabilitation

ClinConnect Summary

This clinical trial, called "Rehabilitation of Visual Function After Brain Injury," is studying a new training program called Neuro Vision Technology (NVT) to help people with vision problems caused by brain injuries, such as strokes or traumatic brain injuries. Many individuals who suffer from these conditions experience significant vision impairments, which can greatly affect their daily lives, balance, and overall quality of life. The goal of this study is to see if the NVT program can lead to meaningful and lasting improvements in vision and daily functioning for those affected.

To participate in the trial, individuals need to be at least 14 years old and have experienced a brain injury that has caused serious vision impairment. They should have some remaining eyesight (at least 6/18 vision) and must be within 6 weeks to 9 months after their injury. Participants will undergo assessments of their vision, mental health, and overall quality of life throughout the study. This research is important because it could lead to better rehabilitation options for people with visual impairments after brain injuries, benefiting both patients and healthcare providers.

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 14 years or older with brain injury.
  • Persons who experience significant vision impairment.
  • Eye sight 6/18 or better.
  • The time from symptoms onset to study inclusion is between 6 weeks and 9 months.
  • Exclusion criteria:
  • Cognitive dysfunction.
  • Persons with anosognosia or severe neglect.
  • Inability to move independently at least 35 meters with or without assistance, including wheelchairs.
  • Inability to understand Danish or with communication disorders that prevent participation in tests.
  • Terminal disorder, other progressive disorder.
  • Significant abuse of alcohol or euphoric or narcotic drugs.
  • Serious disorders such as mental illness, especially severe depression.
  • New brain injury or other significant disorders emerging after study inclusion.
  • Impaired vision not due to brain damage, where the disorder is not considered to be permanent or where the field of vision does not cause significant disability.

About University Hospital, Gentofte, Copenhagen

University Hospital Gentofte, located in Copenhagen, is a leading academic medical center renowned for its commitment to advanced healthcare and innovative research. As a prominent sponsor of clinical trials, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry, facilitating the development of new therapies and treatment protocols. With a multidisciplinary team of experts and state-of-the-art facilities, University Hospital Gentofte plays a pivotal role in enhancing patient care and contributing to the global medical community through its dedication to clinical research and education.

Locations

Copenhagen, Hellerup, Denmark

Patients applied

0 patients applied

Trial Officials

Karsten Overgaard, MD

Study Chair

Copenhagen University Hospital at Herlev

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials